Nyxoah SA (NYXH) is a promising global healthcare innovator that is dedicated to improving well-being and quality of life for people suffering from obstructive sleep apnea (OSA). The company is renowned for developing and introducing the Genio® system, the world’s first and only leadless, battery-free and minimally invasive neurostimulator implant, specifically created to combat OSA.
The company was founded in 2009 and has its corporate headquarters in Mont-Saint-Guibert, Belgium, while maintaining a presence in Australia and the United States as well. Nyxoah SA emphasizes a patient-centered approach, with a focused commitment to offering transformative treatment options for patients whose lives are significantly affected by the challenges of OSA.
The company's flagship Genio® system represents a pioneering leap in OSA treatment technology. The inventive system employs bilateral stimulation to the hypoglossal nerve, ensuring that a patient's airway remains constantly open while they sleep. Unlike other solutions on the market, it is a fully implantable device that is both battery-free and leadless, making it less intrusive and uncomfortable for patients. The device can be personalizing to each individual, ensuring patient-centric and efficient treatment.
In addition to its disruptive technological innovation, Nyxoah SA shows a strong commitment to clinical excellence. The company runs various studies to monitor and gather data on the long-term efficacy and safety of its Genio® system, with presented clinical results suggesting promising improvements in sleep, quality of life, and cardiovascular outcomes for OSA patients.
The company is led by a team of experienced and passionate professionals who have a strong track record in OSA focused medical device companies. CEO Olivier Taelman, joined by a diverse and internationally experienced executive management team, is steering the company towards fulfilling its mission of changing the lives of people who experience sleep apnea.
The shares of Nyxoah SA have been listed on the regulated market of Euronext Brussels since September 2020 under the symbol NYXH. This listing represents a significant milestone which enabled the company to broaden its shareholder base and secure the necessary funding to accelerate its commercial and technological development plans.
Overall, Nyxoah SA is more than just a medical technology company. It is a beacon of hope for OSA patients globally, consistently focused on delivering innovative, user-friendly, and effective treatment options for a disorder that compromises the quality of life of millions each year. Through its revolutionary products and clinical commitment, Nyxoah SA is undoubtedly paving the way for a profound transformation in sleep apnea care.